Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• The BEGIN program extensively evaluated insulin degludec in diverse patient populations with type 1 and type 2 diabetes.
• Studies encompassed insulin-naive and insulin-treated type 2 diabetes, as well as type 1 diabetes.

Purpose of the Study:

• To assess the efficacy of once-daily insulin degludec in various diabetes management regimens.
• To investigate insulin degludec's performance in basal-bolus, basal-plus-oral, and basal-versus-oral therapy settings.
• To explore the impact of flexible dosing on patient adherence and therapeutic outcomes.

Main Methods:

• Phase 3 clinical trials within the BEGIN program.
• Comparison of insulin degludec efficacy against standard treatment comparators.
• Evaluation of different therapeutic strategies including basal-bolus, basal-plus-oral, and basal-versus-oral regimens.
• Assessment of flexible dosing schedules.

Main Results:

• Insulin degludec demonstrated non-inferiority to comparators in reducing HbA1c levels across all investigated trials.
• Efficacy was established for once-daily administration of insulin degludec.
• Flexible dosing emerged as a notable feature, potentially improving patient adherence.

Conclusions:

• Once-daily insulin degludec is an effective treatment for type 1 and type 2 diabetes, achieving glycemic control comparable to existing therapies.
• The flexible dosing schedule of insulin degludec offers a potential advantage for improving patient adherence and overall treatment success.
• The BEGIN program provides robust evidence supporting the use of insulin degludec in various diabetes management contexts.